---
document_datetime: 2023-09-21 17:01:53
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/natpar-epar-all-authorised-presentations_en.pdf
document_name: natpar-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9252602
conversion_datetime: 2025-12-20 16:55:42.216811
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                           | Route of Administration   | Immediate Packaging            | Pack size    |
|------------------|-------------------|------------|-----------------------------------------------|---------------------------|--------------------------------|--------------|
| EU/1/15/1078/001 | Natpar            | 25 µg      | Powder and solvent for solution for injection | Subcutaneous use          | Dual-Chamber Cartridge (glass) | 2 cartridges |
| EU/1/15/1078/002 | Natpar            | 50 µg      | Powder and solvent for solution for injection | Subcutaneous use          | Dual-Chamber Cartridge (glass) | 2 cartridges |
| EU/1/15/1078/003 | Natpar            | 75 µg      | Powder and solvent for solution for injection | Subcutaneous use          | Dual-Chamber Cartridge (glass) | 2 cartridges |
| EU/1/15/1078/004 | Natpar            | 100 µg     | Powder and solvent for solution for injection | Subcutaneous use          | Dual-Chamber Cartridge (glass) | 2 cartridges |